Science

Mar 5, 2025, 10:04

Myeloma Paper of the Day, March 5th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Management of CRS related to teclistamab in patients with relapsed/refractory myeloma can be successful with as little as one dexamethasone dose of 10 mg and without compromising the response rate.”

“Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma”

Authors: James Davis, Jordan Snyder, Mikhaila Rice, Zahra Mahmoudjafari, Victoria Nachar et al.

More posts featuring Robert Orlowski.

cancer James Davis Jordan Snyder Mikhaila Rice Myeloma Paper of the Day OncoDaily Oncology relapsed/refractory myeloma Robert Orlowski RRMM Victoria Nachar Zahra Mahmoudjafari

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma